Astellas Pharma Inc 2012 AR2
The report highlights Astellas Pharma Inc.'s integration of its Annual Report and CSR report for fiscal 2011. The company achieved consolidated net sales of 969.4 billion yen, driven by growth in global products like Vesicare and Prograf. Key milestones included becoming a signatory to the United Nations Global Compact in November 2011 and winning the Grand Prize in Japan's J-Win Diversity Awards. Astellas also advanced its oncology pipeline with positive trial results for enzalutamide and tivozanib, and implemented environmental initiatives such as wind turbine power generation at its Kerry Plant in Ireland.
Company: Astellas Pharma Inc
Sector: Manufacturing
Country: Japan
Year: 2012
Type: AR2
Pages: 140
Back to company
Astellas Pharma Inc
Annual Report
The report highlights Astellas Pharma Inc.'s integration of its Annual Report and CSR report for fiscal 2011. The company achieved consolidated net sales of 969.4 billion yen, driven by growth in global products like Vesicare and Prograf. Key milestones included becoming a signatory to the United Nations Global Compact in November 2011 and winning the Grand Prize in Japan's J-Win Diversity Awards. Astellas also advanced its oncology pipeline with positive trial results for enzalutamide and tivozanib, and implemented environmental initiatives such as wind turbine power generation at its Kerry Plant in Ireland.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2012
Reporting Period
Apr 1, 2011 - Mar 31, 2012
Fiscal Year
2011
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Employees